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SUMMARY. Single nucleotide polymorphisms (SNPs) near the
IL28B gene have been shown to be associated with response
to treatment for chronic hepatitis C and also with sponta-
neous clearance of hepatitis C virus (HCV) infection. We
analysed the association between IL28B genetic variants and
spontaneous clearance of HCV infection in 376 HCV-infected
Chinese paid plasma donors. Genotyping of eight SNPs near
the IL28B region was performed by the iPLEX system
(MassARRAY SNP Genotyping; Sequenom) in all donors,
and sequencing was performed on all 80 donors who cleared
HCV and on 160 of 296 donors who did not clear HCV to
validate the genotypes. Eighty (21.3%) donors spontane-
ously cleared HCV. Four SNPs were significantly associated
with spontaneous HCV clearance: rs8099917 TT (vs GT),
rs8105790 TT (vs CT), rs12980275 AA (vs AG) and
rs10853728 CC (vs CG or GG) with OR (95% CI) 15.27
(2.07–112.50), 14.88 (2.02–109.72), 7.92 (1.88–33.32)
and 2.32 (1.22–4.42) respectively. No association between
the other four IL28B SNPs including rs12979860 and
spontaneous HCV clearance was found. Women had a
higher rate of spontaneous HCV clearance than men [56/
213 (26.3%) vs 24/163 (14.6%), P = 0.007], and this was
true even after stratification for IL28B genotypes with OR of
1.9–2.2 among those with favourable genotypes. Our results
confirmed that IL28B polymorphism is associated with
spontaneous clearance of HCV in Chinese subjects, but the
SNPs that predict HCV clearance in Chinese subjects were
different from those reported in Caucasians. Women were
more likely to clear HCV infection regardless of IL28B
genotypes.
Keywords: acute hepatitis C, chronic hepatitis C, gender,
immune recovery.
INTRODUCTION
Hepatitis C virus (HCV) infection is rated by the World
Health Organization as a global health problem, based on its
prevalence, the high rate (50–85%) of chronicity, the rate of
severe complications such as cirrhosis and hepatocellular
carcinoma, as well as the high costs of antiviral therapy and
liver transplantation [1–3].
There is a significant difference in response to treatment
with pegylated interferon plus ribavirin in patients of dif-
ferent race or ethnicity, with sustained virological response
rates of 28%, 34%, 52% and 76% in African American,
Hispanic, Caucasian American and Asian patients respec-
tively with genotype 1 HCV infection [4–7]. Likewise, racial
differences in the rate of spontaneous viral clearance have
been reported [8,9]. These racial differences suggest a
genetic influence on HCV outcome.
Ge et al. [10] identified a key role for variation in a region
close to the interleukin-28B (IL28B) gene on chromosome
19, which codes for interferon-lambda-3, in predicting
response to pegylated interferon plus ribavirin therapy in
patients with genotype 1 chronic HCV infection. This finding
has been confirmed in other independent cohorts [11–13].
In addition, the IL28B single nucleotide polymorphism (SNP)
most strongly associated with treatment response,
rs12979860, has also been shown to be significantly asso-
ciated with spontaneous hepatitis C clearance [14–16].
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confidence intervals; DBil, direct bilirubin; HCV, hepatitis C virus;
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Tanaka et al. [17] found other SNPs in close proximity to
IL28B that were associated with treatment response in Jap-
anese patients, with rs8099917 and rs12980275 having
the strongest association. Rauch et al. [12] also reported that
rs8099917 was significantly associated with treatment
response as well as with spontaneous clearance of HCV
infection in Swiss and German patients. An association
between rs8099917 and spontaneous HCV clearance was
also shown in a study of Spanish patients [18].
Data on the association between IL28B genetic variants
and treatment response or spontaneous viral clearance in
Chinese patients with HCV infection are limited. In a study of
2371 persons from different continents, Thomas et al. [14]
found that the frequency of the C allele at rs12979860 was
roughly 95% among Chinese, 70% among Caucasians and
25–40% among Africans. Ge et al. [10] noted that the
linkage between rs12979860 and rs8099917 is high
among Caucasians but low among African Americans.
These data suggest that the IL28B variants that have the
strongest association with spontaneous HCV clearance and
response to HCV treatment in different racial/ethnic groups
may be different.
Between 1972 and 1990, several outbreaks of non-A, non-
B hepatitis linked to plasma donation occurred at plasma-
pheresis centres inHebei Province GuanCounty, China. These
donors have been followed for 12–19 years after initial doc-
umentation of HCV infection and roughly 20% have cleared
HCV infection spontaneously. This cohort provided a unique
opportunity to evaluate the role of host genetics in the out-
come of HCV infection in a populationwith fairly homogenous
ethnic background. Here, we present data on the association
between IL28B genetic variation and spontaneous HCV
clearance in these HCV-infected plasma donors.
PATIENTS AND METHODS
Patient population
Commercial plasma donation was introduced in China in the
1970s. Prior to each donation, the donors were required to
have normal alanine aminotransferase (ALT) and no evi-
dence of hepatitis B virus (HBV) infection based on negative
test result for hepatitis B surface antigen (HBsAg). Never-
theless, incidences of non-A and non-B hepatitis continued
to occur, and multiple outbreaks among six villages and one
town occurred in Hebei Province Guan County between
1972 and 1990. The cause of these outbreaks was believed
to be related to the return of red cells to donors through
contaminated transfusion lines. Post-transfusion non-A,
non-B hepatitis outbreaks also occurred among the plasma
recipients; however, this study was focused on the donors.
After hepatitis C testing became available, donors from five
villages and one town were tested for hepatitis C antibody
(anti-HCV) in 1991, and donors from the sixth village were
tested for anti-HCV in 1998. Of the 864 registered paid
donors, 792 (91.7%) came back for anti-HCV testing and
450 (56.8%) of these 792 tested positive. Donors who tested
positive for anti-HCV were invited to return for follow-up
assessment every 5–6 years between 1991 and 2008 and
once a year thereafter. At each visit, the donors were eval-
uated and blood was tested for anti-HCV and ALT. HCV RNA
was tested during follow-up visits in 2002, 2009 and 2010.
All donors who previously tested positive for anti-HCV were
invited to participate in a study of IL28B genetic variation
during their follow-up visit in 2010. Blood was drawn for
biochemical tests, HCV RNA, HCV genotype and IL28B SNPs
during the 2010 visit. HCV clearance was defined as unde-
tectable HCV RNA on at least two follow-up evaluations
including the visit in 2010 in subjects who were anti-HCV
positive during initial screening in 1991 or 1998. All donors
in our study were of Han ancestry.
The Ethical Committee of Human Experimentation in
Peking University Peoples Hospital approved the study, and
the study was performed in accordance with the Helsinki
Declaration of 1975. The plasma donors were enrolled after
providing written informed consent for the follow-up study,
and additional consent for genetic testing was provided
during the 2010 visit.
Biochemical tests
Fasting blood samples collected at each follow-up visit were
tested for ALT, aspartate aminotransferase (AST), c-glutam-
yltransferase (c-GT), alkaline phosphatase, total bilirubin
(TBil), direct bilirubin, total protein and albumin by an auto-
mated biochemical analyser 7600 (Hitachi, Tokyo, Japan).
Virology tests
Tests for anti-HCV were carried out using enzyme immuno-
assay (Chiron, Emeryville, CA, USA) between 1991 and 2005
and chemiluminescent microparticle immunoassay (Archi-
tect; Abbott, Chicago, IL, USA) after 2005. HCV RNA was
quantified with real-time fluorescence quantitative assay (PG
Biotech Company, Shenzhen, China) that has a lower limit of
detection of 500 IU/mL between 2002 and 2008 and with
Cobas Ampliprep/Cobas Taqman HCV assay (Roche Molecu-
lar Diagnostics, Branchburg, NJ, USA) that has a lower limit of
detection of 15 IU/mL after 2008. HCV genotype was deter-
mined with restriction fragment length polymorphism [19].
HBsAg (Abbott) and anti-HIV were detected by enzyme
immunoassay (BioMe´rieux, Boxtel, the Netherlands).
IL28B SNPs genotyping
The genomic region associated with response to hepatitis C
treatment identified by Ge et al. [10] and Tanaka et al. [17]
contains several highly linked SNPs around the IL28B gene.
In our cohort, we selected the following SNPs for genotyp-
ing: rs12979860, rs10853728, rs11881222, rs12980275,
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rs4803219, rs4803223, rs8099917 and rs8105790. DNA
from the subjects was extracted from peripheral blood using
standard methods. Genotyping was performed by the iPLEX
system (MassARRAY SNP Genotyping; Sequenom, San
Diego, CA, USA) for all 376 donors. DNA from the donors
was blind coded and tested using a 384 format Spectro-
CHIP microarray (Sequenom). A matrix-assisted laser
desorption/ionization time-of-flight mass spectrometer was
used for data acquisitions from the SpectroCHIP. Results
were analysed using Sequenoms MassARRAY RT software
(Sequenom). To validate the results of the iPLEX system, we
sequenced the region surrounding the IL28B gene that
covered the eight SNPs for all donors who cleared HCV and a
random selection of approximately 50% of the donors who
did not clear HCV. Samples were amplified, and the ampli-
cons were subjected to direct sequencing using the Big Dyes
Termination version 1.1 kit (ABI) and the ABI Prism 3730
genetic analyser (Applied Biosystems, Foster City, CA, USA).
Sequence results were analysed using Polyphred software
(Applied Biosystems). Results of the iPLEX system and direct
sequencing were compared.
Statistical analysis
Genotype frequencies were obtained by direct counting, and
statistical analysis was performed by the chi-square test.
Qualitative data were also analysed by the chi-square test and
odds ratio (OR) with 95% confidence intervals (95% CI).
Median values of quantitative variables were compared using
a nonparametric test (Mann–Whitney two-tailed test).
P-values <0.05 were considered statistically significant. The
statistical software package used was SPSS 13.0 for Windows
(SPSS Inc., Chicago, IL, USA).
RESULTS
Rate of spontaneous HCV clearance
Of the 450 donors who tested positive for anti-HCV in 1991
or 1998, 36 had died (18 because of liver diseases), and 33
were lost to follow-up by May 2010 (Fig. 1). Five donors
with HBV co-infection were excluded. The remaining 376
HCV-infected plasma donors were tested for IL28B SNPs,
163 were men and 213 women, with a mean age of
53.2 ± 8.0 years and a mean BMI of 24.5 ± 3.2 (kg/m2) at
the time of the study. None of the donors had received
hepatitis C treatment because all of them were farmers and
their medical insurance did not cover hepatitis C treatment.
All the donors were serum anti-HIV negative. Eighty
(21.3%) donors had spontaneous clearance of HCV infection
(95% CI: 17.1–25.4). All 80 remained anti-HCV positive in
2010; of these, 70 had sample/cutoff (S/CO) ratio ‡5 and 10
had S/CO ratio <5 on the anti-HCV test in 2010.
Spontaneous viral clearance was more likely to occur in
women than in men, 26.3% (56/213) vs 14.7% (24/163)
(P = 0.007). As the donors were not regularly followed up
before 1991 or 1998 and most had no symptoms of acute
hepatitis during the outbreaks, the onset of infection and the
severity of the acute infection could not be ascertained.
There was no correlation between age at the time of study
and spontaneous HCV clearance. All the donors had ALT
tested at least once during the outbreaks, and 153 (40.7%)
had elevated ALT on more than one occasion during the
outbreaks. The rate of spontaneous HCV clearance was
similar in donors with and without elevated ALT during the
outbreaks [39/153 (25.5%) vs 41/223 (18.4%) P = 0.10].
During the 2010 visit, donors who had persistent HCV
infection had significantly higher mean ALT, AST and c-GT
and lower platelet count than those who cleared HCV. Of the
296 donors who were still HCV RNA positive, 83.8%, 12.8%
and 3.4% had HCV genotype 1b, 2a and 1b/2a infection,
respectively.
Frequency of IL28B SNPs
Analysis of the IL28B genotype results of 240 donors (80
with spontaneous HCV clearance and 160 with persistent
HCV infection) who were tested by both the iPLEX system
and by sequencing showed a concordance rate of 97.8–
100% for the eight SNPs studied; therefore, the results of the
iPLEX system will be presented in this study.
Of the 376 donors, 180 (48.5%, 95% CI: 43.4–53.6) were
homozygous for CC, 189 (50.9%, 95% CI: 45.9–56.0) were
heterozygous (CT) and only 2 (0.5%, 95% CI: )0.2–1.3)
were homozygous for TT at rs12979860, reflecting a C allele
frequency of 74.0% (95% CI: 70.8–77.2). Frequency of the
other IL28B SNPs is shown in Table 1. No significant devi-
ations in standard genotype quality control according to the
Hardy–Weinberg Equilibrium for six SNPs were noted
(rs12979860, rs10853728, rs12980275, rs4803223,
rs8099917 and rs8105790), while there were significant
deviations for two SNPs (rs11881222 and rs4803219).
Association between IL28B SNPs and spontaneous
clearance of HCV infection
Spontaneous HCV clearance was associated with four of the
eight IL28B SNPs tested. The IL28B genetic variants
rs8099917 [TT vs GT, OR 15.3 (95% CI: 2.1–112.5),
P = 0.002], rs8105790 [TT vs CT, OR 14.9 (95% CI: 2.0–
109.8), P = 0.0024], rs12980275 [AA vs AG, OR 7.9
(95% CI: 1.9–33.3), P = 0.0043] and rs10853728 [CC vs
CG or GG, OR 2.3 (95% CI: 1.2–4.4), P = 0.0206] were
associated with a significantly higher rate of spontaneous
clearance of HCV (Table 2). Thus, for rs8099917, the SNP
with the strongest association with spontaneous HCV
clearance, 24.1% of TT homozygous subjects (77/319; 95%
CI: 19.4–28.8) and only 2.0% (1/49, 95% CI: 1.9–6.0) of
GT heterozygous subjects had spontaneous clearance of
HCV.
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The other four IL28B SNPs including rs12979860 were
not associated with the spontaneous clearance of HCV
infection. For rs12979860, spontaneous HCV clearance was
observed in 24% (43/180, 95% CI: 17.7–30.1), 19.1% (36/
189, 95% CI: 13.5–24.7) and 50% (1/2, 95% CI: 19.3–
119.3) subjects with CC, CT and TT genotypes respectively
(P = 0.33).
As women had a higher rate of spontaneous HCV clear-
ance than men, the prevalence of favourable genotypes
between men and women was compared, and the results
showed no significant difference between men and women
for all eight SNPs studied (Table 1). Women were signifi-
cantly more likely to have spontaneous HCV clearance than
men even after stratification for IL28B genotype with odds
ratio of 1.9–2.2 among those with favourable genotypes
(Table 3). As an example, among those with rs8099917 TT
genotype, 29.5% women but only 16.9% men had sponta-
neous HCV clearance, OR 2.1 (95% CI: 1.2–3.6),
P = 0.0093.
Haplotype analysis
Pair-wise linkage disequilibrium between the SNPs is shown
in Fig. 2. Four SNPs (rs12980275, rs8105790,
rs12979860 and rs8099917) were in strong linkage dis-
equilibrium. The haplotype ATCT with favourable alleles in
Fig. 1 Flow diagram showing the
disposition of 864 registered plasma
donors.
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these four SNPs was not associated with spontaneous HCV
clearance. However, donors with the haplotype ATTC,
favourable alleles in the four SNPs that were independently
shown to be associated with spontaneous HCV clearance
(rs12980275, rs8105790, rs8099917 and rs10853728)
were significantly more likely to have spontaneous HCV
clearance than those who did not have this haplotype,
24.8% (64/258) vs 13.5% (14/104), OR 2.1 (95% CI: 1.1–
4.0), P = 0.018.
Multivariate analysis of factors associated with
spontaneous HCV clearance
Multivariate analysis including the following variables –
gender, the four IL28B SNPs that were significant on uni-
variate analysis and the haplotype ATTC comprising
rs12980275, rs8105790, rs8099917 and rs10853728 –
showed that IL28B SNP rs8099917 (OR = 14.88, 95% CI:
2.02–109.7, P = 0.008) was the most significant factor
associated with spontaneous HCV clearance. Addition of the
other three IL28B SNPs or the haplotype ATTC to the SNP
rs8099917 did not improve the association with spontane-
ous HCV clearance.
Gender had an independent effect on spontaneous HCV
clearance, the odds ratio for women to clear HCV infection
in the multivariate model for all donors was 1.95 (95% CI:
1.14–3.32), for donors with rs8099917 TT was 2.05
(95% CI: 1.18–3.53) and for donors with the haplotype
ATTC was 1.97 (95% CI: 1.09–3.55) when compared with
men.
Table 1 IL28B genotype frequencies in anti-hepatitis C virus-positive Chinese paid plasma donors by gender
IL28B genotype n
Detection
rate (%)
All donors Male donors Female donors
Frequency
(%) 95% CI
Frequency
(%) 95% CI
Frequency
(%) 95% CI
rs10853728 373 99.2
CC 269 72.1 67.6–76.7 68.3 61.1–75.5 75.0 69.2–80.8
CG 95 25.5 21.1–29.9 28.6 21.6–35.6 23.1 17.4–28.8
GG 9 2.4 0.9–4.0 3.1 0.4–5.8 1.9 0.06–3.7
rs11881222 370 98.4
AA 18 4.9 2.7–7.1 3.7 0.8–6.6 5.8 2.6–9.0
AG 352 95.1 93.0–97.3 96.3 93.4–99.2 94.2 91.0–97.4
GG 0 0 0 0
rs12979860 371 98.7
CC 180 48.5 43.4–53.6 49.7 42.0–57.4 47.6 40.8–54.4
CT 189 50.9 45.9–56.0 50.3 42.6–58.0 51.4 44.6–58.2
TT 2 0.5 )0.2–1.3 0 1.0 )0.3–2.3
rs12980275 372 98.9
AA 320 86.0 82.5–89.5 84.5 78.9–90.1 87.2 82.7–91.7
AG 52 14.0 10.5–17.5 15.5 9.9–21.1 12.8 8.3–17.3
GG 0 0 0 0
rs4803219 372 98.9
CC 358 96.2 94.3–98.2 95.0 91.6–98.4 97.2 95.0–99.4
CT 14 3.8 1.8–5.7 5.0 1.6–8.4 2.8 0.6–5.0
TT 0 0 0 0
rs4803223 369 98.1
AA 329 89.2 86.0–92.3 85.6 80.2–91.0 91.9 88.2–95.6
AG 38 10.3 7.2–13.4 13.8 8.5–19.1 7.7 4.1–11.3
GG 2 0.5 )0.2–1.3 0.6 )0.5–1.8 0.5 )0.5–1.5
rs8099917 368 97.9
TT 319 86.7 83.2–90.1 84.5 78.9–90.1 88.4 84.0–92.8
GT 49 13.3 9.9–16.8 15.5 9.9–21.1 11.6 7.2–16.0
GG 0 0 0 0 0
rs8105790 362 96.3
TT 315 87.0 83.6–90.5 84.8 79.2–90.4 88.7 84.4–93.0
CT 47 13.0 9.5–16.4 15.2 9.6–20.8 11.3 7.0–15.6
CC 0 0 0 0 0
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Association between IL28B genotype and HCV RNA level
and HCV genotype
Analysis of the HCV RNA levels of the 276 subjects who had
detectable HCV RNA at the 2010 visit showed that there was
no difference in HCV RNA levels between the subjects with
favourable and those with unfavourable genotypes at the
four IL28B SNPs shown to be associated with spontaneous
HCV clearance. There was also no difference in the distri-
bution of HCV genotypes between the subjects with favour-
able and those with unfavourable IL28B genotypes.
DISCUSSION
In this study of 376 HCV-infected Chinese paid plasma
donors, we found that IL28B gene variants were significantly
associated with the spontaneous clearance of HCV infection.
The SNP that had the strongest association with spontane-
ous clearance of HCV infection was rs8099917, and persons
with the TT genotype were 15 times more likely to clear HCV
than those with the GT genotype. However, the SNP
rs12979860 that has been shown to be most strongly
associated with response to pegylated interferon and riba-
virin and to spontaneous HCV clearance in Caucasians and
African Americans was not associated with spontaneous
HCV clearance in our study [10–14].
Thomas et al. [14] studied 1008 subjects in six indepen-
dent cohorts and found that rs12979860 CC genotype was
predictive of spontaneous HCV clearance among individuals
of both European and African ancestry. An association
between rs12979860 CC genotype and spontaneous HCV
clearance was also shown by Tillmann et al. [16] who
Table 2 Association between IL28B
genotype and spontaneous hepatitis C
virus clearance in Chinese paid plasma
donors
IL28B
genotype
Spontaneous
clearance,
n (%)
Persistent
infection,
n (%) OR 95% CI P-value
rs10853728
CC 67 (83.8) 202 (68.9) 2.32 1.22–4.42 0.0206
CG/GG 13 (16.2) 91 (31.1) 1
rs11881222
AA 6 (7.6) 12 (4.1) 1.91 0.69–5.26 0.45
AG 73 (92.4) 279 (95.9) 1
rs12979860
CC 43 (53.8) 137 (47.1) 1.31 0.80–2.15 0.33
CT/TT 37 (46.2) 154 (52.9) 1
rs12980275
AA 77 (97.5) 243 (82.9) 7.92 1.88–33.32 0.0043
AG 2 (2.5) 50 (17.1) 1
rs4803219
CC 80 (100.0) 278 (95.2) 0.12
CT 0 14 (4.8)
rs4803223
AA 73 (94.8) 256 (87.7) 2.57 0.88–7.45 0.19
AG/GG 4 (5.2) 36 (12.3) 1
rs8099917
TT 77 (98.7) 242 (83.5) 15.27 2.07–112.50 0.0020
GT 1 (1.3) 48 (16.6) 1
rs8105790
TT 77 (98.7) 238 (83.8) 14.88 2.02–109.72 0.0024
CT 1 (1.3) 46 (16.2) 1
rs12980275, rs8105790, rs8099917, rs10853728
AA,TT,TT,CC 64 (82.1) 194 (69.7) 2.12 1.13–3.98 0.0175
AG,TC,TG,CG/GG 14 (17.9) 90 (30.3) 1
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studied 190 German women and by Montes-Cano et al. [18]
in a study of 353 Spanish subjects. In all three studies, only
one SNP (rs12979860) was tested. An association between
rs8099917 TT genotype and response to pegylated inter-
feron and ribavirin treatment had been reported in the
studies of Caucasian patients and Japanese patients with
chronic HCV infection [11,12,17]. An association between
rs8099917 TT genotype and spontaneous clearance of HCV
Table 3 Spontaneous hepatitis C virus clearance rate in female vs male donors stratified by IL28B Genotype
IL28B
genotype
Spontaneous
clearance
rate in all
donors (%)
Spontaneous
clearance
rate in
male (%)
Spontaneous
clearance
rate in
female (%)
OR
(female vs male) OR 95% CI P-value
All donors 21.3 14.7 26.3 2.07 1.22–3.51 0.0066
rs10853728
CC 24.9 18.2 29.6 1.89 1.04–3.41 0.0339
CG/GG 13.7 8.7 18.4 2.36 0.67–8.29 0.17
rs12980275
AA 24.1 16.2 29.9 2.21 1.27–3.85 0.0046
AG 3.9 8.0 0.0
rs8099917
TT 24.1 16.9 29.5 2.06 1.19–3.56 0.0093
TG 2.0 4.0 0.0
rs8105790
TT 24.4 17.2 29.8 2.05 1.18–3.56 0.0097
TC 2.1 4.2 0.0
rs12980275, rs8105790, rs8099917, rs10853728
AA, TT, TT, CC 24.8 17.8 29.8 1.97 1.07–3.60 0.0273
AG, TC, TG, CG/GG 13.5 9.8 17.0 1.88 0.58–6.06 0.28
Fig. 2 Pair-wise linkage disequilibrium pattern of the IL28 region. The degree of linkage disequilibrium between any
two SNPs is described by r2 values (among 0.97–1.00). Rs12980275, rs8105790, rs12979860 and rs8099917 are within
a genomic block that encompasses the IL28B gene.
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infection was also demonstrated in a study of 132 predom-
inantly Caucasian patients in Australia and a study of 1362
Swiss and German patients [12,15]. Only two SNPs
(rs8099917 and rs12980275) were tested in the study in
Australia. The study in Switzerland tested more than
500 000 SNPs. Analysis of data from 1213 individuals with
available data at both rs12979860 and rs8099917 found
that rs12979860 genotype was highly associated with
chronic HCV infection and was in strong linkage disequi-
librium with rs8099917 [12].
In this study, we tested eight SNPs and found an associ-
ation between spontaneous HCV clearance and four SNPs
including rs8099917, rs8105790, rs12980275 and
rs10853728 but not rs12979860. Ge et al. [10] had noted
that the linkage between rs8099917 and rs12979860 is
high among Caucasians, but low among African Americans.
We found that rs8099917 was strongly linked to rs12979860
(r2 = 1.00), rs12980275 (r2 = 0.97) and rs8105790
(r2 = 1.00) in our study. In our study, all donors with
rs12979860 CC had rs8099917 TT genotype, but donors
with rs12979860 CT could be rs8099917 TT or TG.
The rs12979860 C allele frequency in the Chinese Han
population (83 subjects from Beijing, China) was reported to
be 93.4% in HapMap and 94–98% in Thomas study of 47
Chinese in Taiwan and 59 Chinese in San Francisco, but it
was only 74% in our study. The rs8099917 T allele fre-
quency in the Chinese Han population was reported to be
93.5% in HapMap and 93.3% in our study. The subjects in
our study all came from one county, Hebei, in the northern
part of China. So, the SNP allele frequencies in our study
might be only representative of the northern local region.
While most Chinese in the major cities of China are of Han
ancestry, other ancestries predominate in some parts of
China. Studies involving larger numbers of Chinese in dif-
ferent regions of China are necessary to determine the pre-
cise frequency of the favourable alleles at rs12979860 and
rs8099917 among Chinese of various ancestries.
In this study, the SNP rs8099917 had the strongest
association with spontaneous HCV clearance. Although
three other SNPs (rs10853728, rs 12980275 and
rs8105790) in the IL28B region were independently asso-
ciated with spontaneous HCV clearance, inclusion of these
three SNPs or the haplotype ATTC with favourable alleles at
these three SNPs plus rs8099917 did not improve the pre-
diction of spontaneous HCV clearance in the multivariate
model compared with rs8099917 alone. Several studies
showed that women were more likely to undergo sponta-
neous HCV clearance than men. One study of 67 persons
with acute HCV infection, 66% of whom were injection drug
users, found that HCV clearance occurred in 34% of women
compared with 3% of men (P < 0.001) [20]. Another study
followed 135 injection drug users with incident HCV infec-
tion and found that the age-adjusted hazard ratio of spon-
taneous HCV clearance for women was 2.91 (95% CI: 1.68–
5.03) [21]. A systematic review of 31 longitudinal studies
that included 314 subjects showed that the relative risk of
spontaneous HCV clearance for men was 0.43 (95% CI:
0.36–0.53) (P = 0.00001) [22].
Two recent studies examined gender, IL28B genetic vari-
ants and spontaneous HCV clearance. In Grebely et al.s [15]
study of 132 Australians, rs8099917 TT genotype (adjusted
hazard ratio 3.78, 95% CI: 1.04–13.76) was the only factor
predicting spontaneous HCV clearance on multivariate
analysis, but female gender and jaundice during the acute
illness were not. In Montes-Cano et al.s [18] study of 352
Spanish subjects, rs12979860 CC genotype was associated
with a higher rate of spontaneous HCV clearance in both
men (72.4% vs 27.6%) and women (72.5% vs 27.5%)
compared with those with CT or TT genotype. In this study,
we found that women had a higher rate of spontaneous HCV
clearance than men, 26.3% vs 14.6%, and this difference
persisted even after stratification for IL28B genotypes.
Among those with rs8099917 TT genotype, women were
twice as likely to have spontaneous HCV clearance as men.
Female gender remained an independent predictor of spon-
taneous HCV clearance in the multivariate model, with OR
of 1.95.
Some studies found that the presence of jaundice or
symptoms during acute HCV infection was associated with
a higher rate of spontaneous HCV clearance [15,16,22].
Tillmann et al. [16] found that jaundice during acute
infection was associated with an increased chance of
spontaneous HCV clearance (42.9% vs 13.7%) in persons
with non-CC genotype at rs12979860, but not in those
with CC genotype (56.3% vs 60.6%). In this study, spon-
taneous HCV clearance rate was similar in donors with and
without documented ALT elevation during the outbreaks,
but the donors were not regularly monitored, and it is
possible that ALT was not tested at the time of acute
infection. We were also not able to determine whether any
of the donors had symptomatic illness or were jaundiced
during the acute infection.
In summary, in this study of a large homogenous cohort
of HCV-infected plasma donors, we found that 21.3% had
spontaneous HCV clearance. We confirmed that IL28B
genotype is associated with spontaneous HCV clearance
with rs8099917 TT genotype showing the strongest asso-
ciation, while rs12979860 CC genotype had no association.
Women had a higher rate of spontaneous HCV clearance
regardless of IL28B genotype. Our results suggest that while
IL28B genotype is associated with spontaneous HCV clear-
ance in patients of diverse racial/ethnic background, the
SNP with the strongest association may vary. Further
studies are needed to confirm this observation and to clarify
whether other factors such as gender and severity of the
acute illness are independent predictors of spontaneous
HCV clearance after correction for IL28B genotype. These
results will help in determining which patients with acute
HCV infection should start on antiviral therapy and which
ones to be monitored.
 2011 Blackwell Publishing Ltd
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